Skip to main content

bortezomib (Velcade®)

 

Following a limited submission

AWMSG advice

Status: Recommended with restrictions

Bortezomib (Velcade®) is recommended as an option for restricted use within NHS Wales for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation. Bortezomib (Velcade®) should be restricted for use in combination with dexamethasone. This recommendation applies only in circumstances where the approved Patient Access Scheme is utilised. Bortezomib (Velcade®) is not recommended for use within NHS Wales in combination with pegylated liposomal doxorubicin.

 Final Recommendation: bortezomib (Velcade) 1807 (PDF, 349Kb)
 Appraisal Report: bortezomib (Velcade) 1807 (PDF, 1.9Mb)

Medicine details

Medicine name bortezomib (Velcade®)
Formulation 3.5 mg powder for solution for injection
Reference number 1807
Indication

In combination with pegylated liposomal doxorubicin or dexamethasone for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation

Company Janssen-Cilag Ltd
BNF chapter Malignant disease & immunosuppression
Submission type Limited
Status Recommended with restrictions
Advice number 2814
NMG meeting date 10/09/2014
AWMSG meeting date 08/10/2014
Ratification by Welsh Government 30/10/2014
Date of issue 31/10/2014
Date of last review 20/12/2017
Commercial arrangement PAS
Follow AWTTC: